Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 2/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 14/20 | 0.45 |
| ▸ | PPARG | P37231 | 13/20 | 0.45 |
| ▸ | PPARD | Q03181 | 12/20 | 0.45 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.41 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.40 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4614758 | 0.88 | FBP1 (0.45) | FBP1CNR2PPARAPPARGPPARD | |
| SCHEMBL4616226 | 0.87 | FBP1 (0.46) | FBP1CNR2PPARAPPARGPPARD | |
| SCHEMBL4616212 | 0.86 | FBP1 (0.44) | FBP1CNR2PPARAPPARGPPARD | |
| SCHEMBL4614921 | 0.86 | FBP1 (0.44) | FBP1CNR2PPARAPPARGPPARD | |
| SCHEMBL14543831 | 0.86 | EPAS1 (0.50) | FBP1PPARAPPARGPPARDABCB11 | |
| SCHEMBL14289654 | 0.85 | PPARA (0.52) | FBP1PPARAPPARGPPARDABCB11 | |
| SCHEMBL1549698 | 0.85 | PPARA (0.57) | FBP1CNR2PPARAPPARGABCB11 | |
| SCHEMBL9700152 | 0.85 | FBP1 (0.54) | FBP1CNR2PPARAPPARGABCB11 | |
| SCHEMBL4615988 | 0.84 | FBP1 (0.47) | FBP1PPARAPPARGPPARDABCB11 | |
| SCHEMBL4616738 | 0.83 | FBP1 (0.50) | FBP1PPARAPPARGABCB11CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1697304-B1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | LILLY CO ELI (US) | 2008-02-20 | — | — | EP | disclosed |
| US-20070082907-A1 | Peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY (IN) | 2007-04-12 | — | — | US | disclosed |
| EP-1697304-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005054176-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082907-A1 | Peroxisome proliferator activated receptor modulators | PPARG, PPARA, PPARD | FBP1 484/4885CNR2 544/4885PPARA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.